Theranexus announces its 2023 annual results and the progress of its projects

Theranexus, a company based in Lyon and specializing in neuroscience, has communicated its financial results for the year 2023 as well as the significant progress of its research programs. In 2023, the company notably advanced the phase 1/2 study of its drug Batten-1, targeting Batten disease, with a phase 3 design approved by the FDA and EMA.

Financially, Theranexus recorded a net result of -€6,828 thousand in 2023, a figure slightly higher than that of 2022. These losses are explained by increased investments in R&D and a drop in operating income, despite optimized management of personnel costs and an improvement in financial results thanks to a favorable interest rate environment.

The company also strengthened its management team with the arrival of Christine Placet as Administrative and Financial Director, succeeding Thierry Lambert. Christine brings solid experience acquired in the biotechnology sector, which constitutes a major asset for Theranexus.

Looking ahead, Theranexus is exploring various financing options to support its future activities, including partnerships and fundraising, in order to continue the development of its innovative pharmaceutical projects in rare neurological diseases.